Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ ICU admission 56% Improvement Relative Risk c19early.org/d Pepkowitz et al. Vitamin D for COVID-19 Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Retrospective 37 patients in the USA Lower ICU admission with higher vitamin D levels (p=0.014) Pepkowitz et al., Research Square, doi:10.21203/rs.3.rs-83262/v1 Favors vitamin D Favors control
Vitamin D Deficiency is Associated with Increased COVID-19 Severity: Prospective Screening of At-Risk Groups is Medically Indicated
Pepkowitz et al., Research Square, doi:10.21203/rs.3.rs-83262/v1 (Preprint)
Pepkowitz et al., Vitamin D Deficiency is Associated with Increased COVID-19 Severity: Prospective Screening of At-Risk Groups.., Research Square, doi:10.21203/rs.3.rs-83262/v1 (Preprint)
Sep 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 37 hospitalized patients in the USA, showing higher risk of ICU admission with vitamin D deficiency.
risk of ICU admission, 55.8% lower, RR 0.44, p = 0.01, high D levels (≥20ng/mL) 9 of 24 (37.5%), low D levels (<20ng/mL) 11 of 13 (84.6%), NNT 2.1, inverted to make RR<1 favor high D levels (≥20ng/mL).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pepkowitz et al., 29 Sep 2020, retrospective, USA, preprint, 7 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: Vitamin D Deficiency is Associated with Increased COVID-19 Severity: Prospective Screening of At-Risk Groups is Medically Indicated Samuel H Pepkowitz MD (  Samuel.Pepkowitz@cshs.org ) Cedars-Sinai Medical Center https://orcid.org/0000-0002-8384-3227 Calvin J Hobel MD Cedars-Sinai Medical Center James M Mirocha MS Cedars-Sinai Medical Center Kimia.Sobhani PhD Cedars-Sinai Medical Center Carissa A Huynh BS Cedars-Sinai Medical Center Harneet Jawanda MD Cedars-Sinai Medical Center Wohaib Hasan PhD Cedars-Sinai Medical Cente Research Article Keywords: COVID-19, Vitamin D Deficiency, Pulmonary Inflammation, ICU Care Posted Date: September 29th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-83262/v1 License:   This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/10 Abstract Non-classical actions of Vitamin D are involved in regulation of the immune system including a role in mitigation of excessive inflammation. We hypothesized that vitamin D deficiency existing prior to SARSCoV-2 infection could contribute to patients developing severe pulmonary compromise as a result of dysfunctional hyperinflammation. Serum vitamin D concentrations of patients experiencing such severe COVID-19 manifestations that they required ICU care at any point of their hospitalization were compared to serum vitamin D concentrations of patients achieving discharge without the need for any ICU care. Having serum vitamin D < 20 ng/mL was significantly associated with increased COVID-19 severity, p=0.001. It is conjectured that population groups know to have low serum vitamin D should be prospectively screened for deficiency and if found emergently treated. Such action could both decrease the maximum severity suffered by infected individuals and lessen the strain on medical resources by decreasing the percentage of COVID-19 hospital admissions requiring ICU care. Background SARS-CoV-2 infection (COVID-19) manifests itself on a clinical spectrum ranging from asymptomatic carriage to life-threatening disease with catastrophic compromise often due to a hyperinflammatory necrotizing pneumonitis [1,2]. African Americans, Native Americans, Hispanic Americans, obese individuals and the elderly are among groups experiencing disproportionately high levels of severe disease compared a to younger, normal Body Mass Index (BMI), Caucasian control population [3,4,5,6,7]. However, instead of attributing these discrepancies to genetic susceptibility or unavoidable effects of aging there is an evolving recognition that asymmetries of socioeconomic status , chronic stress, the availability of routine and acute medical care, and exposure to toxic environmental factors may be primarily responsible for the increased morbidity being suffered by these groups [3,8]. These same groups are also known to be disproportionately 25-hydroxyvitamin D (25VD) insufficient (serum levels of 20-30 ng/dL) or deficient (serum levels<20 ng/dL) [9,10,11]. While the etiology of the necrotizing pulmonary process is no doubt multifactorial, vitamin D deficiency has been targeted as is a candidate factor for abetting some of the dysfunctional hyperinflammation [12,13] occurring in these patients. Vitamin D deficiency affects various macrophage populations generally leading to a dampening of local production of 1,25-dihydroxyvitamin D (1,25VD), the effector molecule of intracrine, autocrine and paracrine actions of vitamin D [14]. Specifically, vitamin D..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit